|
|
|
|
CROs are not just facilitators but strategic innovators essential for delivering new therapies to patients efficiently and safely. Selecting the right CRO is crucial, with factors such as track record, global infrastructure, and commitment to quality influencing clinical trial success.
|
|
|
|
|
The global infectious disease clinical trial landscape has rapidly expanded due to the urgency of emerging threats, technological innovation, and evolving regulatory frameworks. Strategic expansion into high-burden regions, regulatory harmonization, and sustained investment are critical to meeting future infectious disease threats.
|
|
|
|
|
Obesity, a chronic and multifactorial metabolic disease, is a growing global health crisis marked by a sharp rise in prevalence across all demographics and income levels. Read through this comprehensive overview of current and emerging obesity treatments that emphasizes innovations and global research trends.
|
|
|
|
|
Obesity is a complex, multifactorial disease with growing global prevalence and significant health burdens. This report analyzes the current state of global and Asia-Pacific obesity trials, highlighting regional trends, sponsor activity, and preferred endpoints.
|
|
|
|
|
Idiopathic Pulmonary Fibrosis is a progressive and potentially life-threatening lung disease affecting over a million people globally. Clinical trial activity has grown significantly, with most studies in early to mid-development stages focusing on long-term outcomes and RWD.
|
|
|
|
|
|
|
|
|
|
|
|
|
Novotech’s latest global market insights reveals a surge of innovation in Idiopathic Pulmonary Fibrosis (IPF) research.
Since 2020, over 800 industry-sponsored IPF trials have launched worldwide, reflecting robust momentum in addressing this serious condition.
Key highlights:
- Asia-Pacific accounts for 44% of global IPF trial activity, primarily led by Mainland China.
- Investigational therapies include RNA interference, PDE4 inhibitors, monoclonal antibodies, and cell-based treatments.
- Precision trial designs and biomarker-driven methodologies are being increasingly adopted.
- Funding from both private and public sectors continues to support innovation.
- Racial and ethnic disparities in trial participation remain a concern across regions.
Download the full report to learn more about the evolving IPF clinical trial landscape.
|
|
|
